Followers | 17 |
Posts | 4305 |
Boards Moderated | 0 |
Alias Born | 04/13/2016 |
Thursday, April 02, 2020 12:16:30 PM
No. You have to know the number who did receive it and still died. Let's take the study that Rayo referenced recently and look at the numbers:
Untreated Patients: 0% deaths, 0% ICU admissions, 100% recovery
Treated Patients: 3.8% deaths, 11.5% ICU admissions, 85% recovery
Does this give you confidence that the treatment people are promoting as a miracle cure is all that great?
The groups we need to compare are a) randomly assigned to conditions; b) in a double-blind procedure where half receive a placebo; and c) have a sufficiently large sample size. Only when we compare those groups will we know for certain whether or not the treatment is effective.
In spite of the differences in outcomes as shown above, scientists still found evidence for the possibility that the treatment might be effective. The difference in deaths and ICU admissions could be due to a small sample size and the fact that assignment was not random.
Recent KBLB News
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 11/22/2023 09:31:54 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/16/2023 09:30:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:43:51 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/11/2023 08:30:50 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/08/2023 04:15:15 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 09/01/2023 08:30:52 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:35:05 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM